Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Administrative · Pharmacy · Genetics, Pediatrics, PharmacyLow impact

08.00.70e, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)

Effective date
Not stated in the notice
Identified
Jun 19, 2026

Summary

This is a routine annual reissue of Independence Blue Cross policy 08.00.70e on Enzyme Replacement Therapy for Mucopolysaccharidosis with no substantive changes to coverage criteria, dosing, or billing codes. The policy maintains coverage for five FDA-approved enzyme replacement therapies (Aldurazyme, Elaprase, Vimizim, Naglazyme, and Mepsevii) when medical necessity criteria are met.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 4 steps
01No immediate action required.
02This is a routine annual policy reissue with no changes to coverage criteria, dosing requirements, or billing codes.
03Billing and clinical staff should verify that current workflows already align with the documented medical necessity requirements (genetic testing confirmation and specific dosing per FDA labeling for each enzyme therapy).
04No system updates or process changes are necessary at this time.

Codes mentioned

J1322J1458J1743J1931J3397E76.01E76.02E76.03E76.1E76.210E76.29

Original notice

08.00.70e, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.034d, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)LowNo effective date · PharmacyMA08.034d, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)LowEffective Jan 1, 2024 · Pharmacy08.00.70e, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)LowEffective Apr 1, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesGeneticsPediatricsPharmacyCode J1322Code J1458Code J1743Code J1931Code J3397Code E76.01Code E76.02Code E76.03Code E76.1Code E76.210Code E76.29

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account